Alligator Bioscience AB appoints Sibylle Lenz as Chief Executive Officer
Alligator Bioscience AB announced that it has appointed Sibylle Lenz, Pharm. Dr, as its new Chief Executive Officer (CEO). Mrs Lenz, who joins Alligator Bioscience from Dako A/S and who previously has had a long successful career at H. Lundbeck A/S, has significant senior management experience in the pharmaceutical industry and has been appointed to lead the Company as it embarks on a new phase of international clinical and commercial development. Mrs Lenz will take up her position on 1st August 2010.
Sibylle Lenz is an experienced pharmaceutical executive who has held senior positions in the diagnostics and pharmaceutical industry. She joins Alligator Bioscience from Dako A/S, a cancer diagnostics company where she was Vice President, Corporate Business Development.
From 2001 to 2008 Mrs Lenz held a number of senior international commercial positions in H. Lundbeck A/S and prior to that Mrs Lenz gained more than ten years of experience in different research and development positions, also in H. Lundbeck A/S. Mrs Lenz holds a PhD specialized in medicinal chemistry from the Danish University of Pharmaceutical Sciences.
Other news from the department people
